The BRAVATO WG has developed standardized templates to describe the key characteristics of several major vaccine platform technologies, including protein vaccines[2]
The BRAVATO WG has developed standardized templates to describe the key characteristics of several major vaccine platform technologies, including protein vaccines[2]. and Paraguay. The main clinical trials include placebo-controlled phase 2 studies in healthy adults (CT-COV-21), adolescents (CT-COV-22), and elderly population (CT-COV-23) as well as 3 immunobridging phase 3 trials (CT-COV-31, CT-COV-32, and CT-COV-34) in…